Cinryze®
SHP616-302
Phase 3 mab terminated
Quick answer
Cinryze® for Acute Antibody-Mediated Rejection (AMR) is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Acute Antibody-Mediated Rejection (AMR)
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated